Value of new, costly hepatitis drugs rides on SVR, experts say

02/19/2014 | MedPage Today (free registration)

The high price for new hepatitis drugs has drawn attention and experts say the key to determining whether treatments are worth the cost is the rate of sustained virologic response. Researcher Andrea Branch at Mount Sinai Hospital in New York City is monitoring the new drugs and may have some answers later this year, but she says for hepatitis C patients a cure can be priceless. University of Chicago Medical Center's Nancy Reau says the bottom line is more simple: "People with hep C cost money."

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Medical Device Reimbursement Specialist - Regional
Alcon
Fort Worth , TX
Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group
Genentech
94080, CA
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX